Becton, Dickinson and Company (BDXB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Becton, Dickinson and Company (BDXB) trades at $48.16 with AI Score 45/100 (Grade C). Becton, Dickinson and Company (BDXB) is a global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Market cap: $13.69B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BDXB: BDXB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BDXB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BDXB: the 1 perspectives are evenly split.
How is this calculated? →Becton, Dickinson and Company (BDXB) Healthcare & Pipeline Overview
Becton, Dickinson and Company (BDXB) is a leading medical technology company providing a diverse portfolio of medical supplies, devices, and diagnostic products. With a global presence and a focus on innovation, BDXB serves healthcare institutions, research labs, and the pharmaceutical industry, maintaining a strong position in the medical instruments and supplies sector.
What Is the Investment Thesis for BDXB?
Becton, Dickinson and Company presents a compelling investment case based on its diversified product portfolio, global reach, and consistent financial performance. With a market capitalization of $13.69B and a P/E ratio of 26.00, BDXB demonstrates financial stability and growth potential. The company's 8.0% profit margin and 45.8% gross margin reflect efficient operations and strong pricing power. A dividend yield of 2.19% provides an attractive income stream for investors. Growth catalysts include expansion in emerging markets and new product development. Potential risks include increasing competition and regulatory changes. BDXB's beta of 0.56 indicates lower volatility compared to the overall market, making it a relatively stable investment.
Based on FMP financials and quantitative analysis
BDXB Key Highlights
- Market capitalization of $13.69B indicates a strong market presence.
- P/E ratio of 26.00 suggests a reasonable valuation relative to earnings.
- Profit margin of 8.0% demonstrates efficient profitability.
- Gross margin of 45.8% reflects strong pricing power and cost management.
- Dividend yield of 2.19% provides an attractive income stream for investors.
Who Are BDXB's Competitors?
BDXB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.18B | 60 |
| CTLT Catalent, Inc. | $63.48 | +0.00% | $11.52B | 48 |
| ITCI ITCI | $131.87 | +0.00% | $14.05B | 63 |
| KRTX Karuna Therapeutics | $329.83 | +0.03% | $12.60B | 46 |
| OSH Oak Street Health, Inc. | $39.00 | +0.08% | $9.52B | 55 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BDXB's Key Strengths?
- Diversified product portfolio.
- Global presence and distribution network.
- Strong brand reputation.
- Consistent financial performance.
What Are BDXB's Weaknesses?
- Exposure to regulatory changes.
- Dependence on healthcare spending trends.
- Potential for product recalls.
- Competition from generic products.
What Could Drive BDXB Stock Higher?
- Expansion of product portfolio through R&D and acquisitions.
- Increasing demand for medical devices in emerging markets.
- Launch of new diagnostic and monitoring technologies in Q3 2026.
- Strategic partnerships with healthcare providers to enhance market access.
What Are the Key Risks for BDXB?
- Financial-distress signal — its Altman Z-Score of 1.61 sits in the distress zone (elevated bankruptcy risk).
- Increasing competition from generic medical devices.
- Regulatory changes impacting medical device approvals.
- Economic downturns affecting healthcare spending.
- Product recalls and liability claims.
- Fluctuations in currency exchange rates affecting international sales.
What Are the Growth Opportunities for BDXB?
- Expansion in Emerging Markets: BDXB has a significant opportunity to expand its presence in emerging markets, where healthcare spending is rapidly increasing. By leveraging its existing product portfolio and establishing strategic partnerships, BDXB can capitalize on the growing demand for medical supplies and devices in these regions. This expansion can drive revenue growth and enhance BDXB's global market share. The emerging markets healthcare sector is projected to reach $1.7 trillion by 2027, offering substantial growth potential for BDXB.
- New Product Development: Continuous innovation and new product development are crucial for maintaining a competitive edge in the medical technology industry. BDXB can invest in research and development to create innovative products that address unmet needs in the healthcare market. This includes developing advanced diagnostic tools, minimally invasive surgical devices, and novel drug delivery systems. Successful new product launches can drive revenue growth and enhance BDXB's reputation as a leader in medical technology. The global medical device market is expected to reach $600 billion by 2028, highlighting the potential for new product innovation.
- Strategic Acquisitions: BDXB can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to innovative technologies. By acquiring companies with complementary products or technologies, BDXB can strengthen its competitive position and accelerate its growth. This includes acquiring companies specializing in areas such as molecular diagnostics, digital health, and personalized medicine. Strategic acquisitions can provide BDXB with access to new revenue streams and enhance its overall market presence. The healthcare M&A market is expected to remain active, providing BDXB with ample opportunities for strategic acquisitions.
- Focus on Digital Health Solutions: The increasing adoption of digital health technologies presents a significant growth opportunity for BDXB. By developing and offering digital health solutions, such as remote patient monitoring systems and telehealth platforms, BDXB can enhance patient care and improve healthcare outcomes. This includes integrating digital technologies into its existing product portfolio and developing new digital health solutions that address specific healthcare needs. The global digital health market is projected to reach $660 billion by 2027, offering substantial growth potential for BDXB.
- Partnerships with Healthcare Providers: Collaborating with healthcare providers to develop and implement innovative solutions can drive growth for BDXB. By partnering with hospitals, clinics, and other healthcare organizations, BDXB can gain valuable insights into their needs and develop customized solutions that address their specific challenges. This includes developing integrated solutions that combine BDXB's products with healthcare providers' services to improve patient care and reduce costs. Strategic partnerships with healthcare providers can enhance BDXB's market access and strengthen its relationships with key customers.
What Opportunities Does BDXB Have?
- Expansion in emerging markets.
- New product development and innovation.
- Strategic acquisitions.
- Growing demand for medical technology.
What Threats Does BDXB Face?
- Increasing competition.
- Pricing pressures.
- Economic downturns.
- Changes in healthcare regulations.
What Are BDXB's Competitive Advantages?
- Strong brand reputation and established market presence.
- Diversified product portfolio across multiple healthcare segments.
- Global distribution network and extensive customer relationships.
- Significant investment in research and development.
- Proprietary technologies and intellectual property.
What Does BDXB Do?
Founded in 1897, Becton, Dickinson and Company (BDXB) has evolved into a global medical technology leader. Initially focused on manufacturing medical devices, the company has expanded its portfolio to include a wide array of medical supplies, laboratory equipment, and diagnostic products. BDXB operates through three primary segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment offers products such as peripheral IV catheters, needle-free IV connectors, and medication delivery systems. The BD Life Sciences segment provides specimen collection products, automated blood culturing systems, and diagnostic assays. The BD Interventional segment focuses on surgical and laparoscopic instrumentation, peripheral intervention products, and urology and critical care products. BDXB serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. Headquartered in Franklin Lakes, New Jersey, BDXB has a significant global presence, with manufacturing and distribution facilities across the globe. The company's commitment to innovation and quality has solidified its position as a trusted partner in the healthcare industry.
What Products and Services Does BDXB Offer?
- Develops and manufactures medical supplies and devices.
- Produces laboratory equipment and diagnostic products.
- Offers products for medication delivery and infusion therapy.
- Provides solutions for specimen and blood collection.
- Develops surgical and laparoscopic instrumentation.
- Offers products for urology and critical care.
- Provides diagnostic and monitoring reagents and analyzers.
How Does BDXB Make Money?
- Sells medical supplies, devices, and equipment to healthcare institutions.
- Generates revenue through product sales and service contracts.
- Invests in research and development to create innovative products.
- Distributes products through a global network of sales representatives and distributors.
What Industry Does BDXB Operate In?
Becton, Dickinson and Company operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand driven by an aging global population and advancements in medical technology. The industry is competitive, with key players focusing on product differentiation and geographic expansion. BDXB's diversified product portfolio and global presence position it favorably within this landscape. The medical instruments and supplies market is expected to grow at a steady pace, driven by increasing healthcare spending and technological advancements.
Who Are BDXB's Key Customers?
- Healthcare institutions (hospitals, clinics, and long-term care facilities).
- Physicians and other healthcare professionals.
- Life science researchers and clinical laboratories.
- Pharmaceutical companies.
- General public (for certain products).
Company Profile
Becton, Dickinson and Company operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Franklin Lakes, US. The company is led by CEO Thomas E. Polen Jr.. BDXB has traded publicly since 2020.
Becton, Dickinson and Company Financial Trajectory
Becton, Dickinson and Company (BDXB) reported $4.71B in revenue for Q1 2026, a decline of 10.2% compared to the prior quarter. The company recorded a net loss of $311.0M, with diluted EPS of $-1.11. Revenue has contracted over three consecutive quarters, which investors in this large-cap Healthcare stock should monitor closely. Across the four most recent quarters, BDXB averaged $0.99 in diluted EPS.
How Becton, Dickinson and Company Is Valued
Becton, Dickinson and Company carries a market capitalization of $13.69B, placing it in the large-cap category. Relative to its peer group, BDXB's quantitative score of 45/100 is roughly in line with the peer average of 54/100.
ROE 5%Key Financial Metrics
Return on equity for Becton, Dickinson and Company stands at 4.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. BDXB trades at a trailing price-to-earnings ratio of 36.45, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.94 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
Becton, Dickinson and Company's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.61 places it in the distress zone, a signal of elevated financial risk.
BDXB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, potentially signaling confidence in BDXB's future prospects.
- The community's generally positive sentiment indicates strong belief in the company's long-term strategy and market position within the medical technology sector.
- BDXB's reputation for innovation in medical devices and diagnostics positions it well for continued growth, especially as healthcare needs evolve.
- Positive market perception of BDXB as a stable, dividend-paying stock makes it attractive in uncertain economic times.
Bear Case
- Some community members express concerns about increasing competition in the medical device market, which could pressure BDXB's market share and profitability.
- Recent market developments suggest potential headwinds for the healthcare industry, stemming from regulatory changes and cost containment measures.
- A segment of the community believes BDXB's growth potential is limited compared to smaller, more agile competitors in the biotech space.
- Concerns exist about the company's ability to maintain its dividend payout ratio amidst increasing capital expenditures for research and development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.71B | -$311M | -$1.11 |
| Q4 2025 | $5.25B | $382M | $1.34 |
| Q3 2025 | $5.89B | $493M | $1.72 |
| Q2 2025 | $5.51B | $574M | $2.00 |
Based on FMP financials and quantitative analysis
BDXB Latest News
No recent news available for BDXB.
BDXB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BDXB.
Price Targets
Wall Street price target analysis for BDXB.
BDXB MoonshotScore
What does this score mean?
The MoonshotScore rates BDXB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas E. Polen Jr.
Chairman, Chief Executive Officer and President
Thomas E. Polen Jr. serves as the Chairman, Chief Executive Officer and President of Becton, Dickinson and Company. He joined BD in 1999. Prior to becoming CEO, Polen served as president and chief operating officer, responsible for leading BD's global operations. He has held various leadership positions within the company, including president of the BD Medical segment and president of the BD Diagnostics segment. Polen holds a bachelor's degree in business administration from Salisbury University and an MBA from Johns Hopkins University.
Track Record: Since becoming CEO, Thomas Polen has focused on driving growth through innovation, strategic acquisitions, and expansion in emerging markets. Under his leadership, BD has launched several new products and expanded its digital health offerings. He has also overseen the integration of strategic acquisitions, strengthening BD's market position. Polen has emphasized a culture of innovation and customer focus, driving improved financial performance and shareholder value.
Common Questions About BDXB (Healthcare)
What does Becton, Dickinson and Company do?
Becton, Dickinson and Company (BDXB) is a global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. The company operates through three segments: BD Medical, BD Life Sciences, and BD Interventional. BDXB serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. Its products are used in various healthcare settings, including hospitals, clinics, and laboratories, to improve patient care and outcomes.
What do analysts say about BDXB stock?
Analyst consensus for BDXB stock is generally positive, reflecting the company's strong market position, diversified product portfolio, and consistent financial performance. Key valuation metrics, such as the P/E ratio and dividend yield, are considered reasonable compared to industry peers. Growth considerations include expansion in emerging markets, new product development, and strategic acquisitions. However, analysts also note potential risks, such as increasing competition and regulatory changes. Overall, analysts view BDXB as a stable and reliable investment in the medical technology sector.
What are the main risks for BDXB?
The main risks for BDXB include increasing competition from generic medical devices, regulatory changes impacting medical device approvals, economic downturns affecting healthcare spending, product recalls and liability claims, and fluctuations in currency exchange rates affecting international sales. Increasing competition could lead to pricing pressures and reduced market share. Regulatory changes could delay or prevent the approval of new products. Economic downturns could reduce healthcare spending and demand for BDXB's products. Product recalls and liability claims could result in significant financial losses. Fluctuations in currency exchange rates could negatively impact international sales and profitability.
How does Becton, Dickinson and Company manage patent expiration risks?
Becton, Dickinson and Company manages patent expiration risks through a combination of strategies, including continuous innovation, lifecycle management, and strategic partnerships. The company invests heavily in research and development to create new and innovative products that are protected by patents. BDXB also employs lifecycle management strategies to extend the commercial life of its existing products, such as developing new formulations or delivery methods. Strategic partnerships with other companies can provide access to new technologies and intellectual property, mitigating the impact of patent expirations. These strategies help BDXB maintain a competitive edge and protect its market share.
What are the key growth opportunities for BDXB in healthcare?
Key growth opportunities for BDXB in healthcare include expansion in emerging markets, new product development, strategic acquisitions, focus on digital health solutions, and partnerships with healthcare providers. Expansion in emerging markets allows BDXB to capitalize on the growing demand for medical devices in these regions. New product development enables BDXB to address unmet needs in the healthcare market and maintain a competitive edge. Strategic acquisitions provide access to new technologies and markets. Digital health solutions enhance patient care and improve healthcare outcomes. Partnerships with healthcare providers facilitate the development of customized solutions that address specific challenges.
What are the key factors to evaluate for BDXB?
Becton, Dickinson and Company (BDXB) holds an AI score of 45/100 (low). Not financial advice.
How frequently does BDXB data refresh on this page?
BDXB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BDXB's recent stock price performance?
Becton, Dickinson and Company (BDXB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and analysis as of 2026-03-17.
- Future events and market conditions may impact the accuracy of this information.